Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of nattokinase in preparing cerebral protective agent type drugs

A technology of nattokinase and brain protection, which is applied in the direction of drug combination, medical formula, medical preparations containing active ingredients, etc., to achieve the effect of exact drug effect, small dosage and low cost

Active Publication Date: 2012-11-07
CHENGDU DIAO JIUHONG PHARMA FAB
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there have been no records or reports of nattokinase itself, its derivatives or modifications, and biologically active substances containing all or part of the amino acid sequence of nattokinase as brain protective agents or neuroprotective agents, nor have they been used as brain protective agents. Protective or neuroprotective agents are used in the treatment of ischemic stroke, cerebral edema, and nervous system damage caused by various causes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nattokinase in preparing cerebral protective agent type drugs
  • Application of nattokinase in preparing cerebral protective agent type drugs
  • Application of nattokinase in preparing cerebral protective agent type drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 The therapeutic effect of nattokinase on focal cerebral ischemia in rats induced by photochemical method

[0035] 1.1 Test material

[0036] Nattokinase (abbreviated as DANK), white freeze-dried flocculent powder, provided by Chengdu Di'ao Pharmaceutical Group, batch number: 20071225, each 1.5g of DANK is equivalent to 200mg of pure product, after precise weighing, dissolve and dilute with normal saline for injection to the desired concentration.

[0037] Edaravone injection, colorless and clear liquid, produced by Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd., batch number: 80-071009, used as the original solution.

[0038] Wistar rats were provided by Shanghai Slack Experimental Animal Co., Ltd., animal certificate number: SCXK (Shanghai) 2003-0003. The animals were kept in a positive pressure purification and ventilation animal room with a room temperature of 23±2°C and a humidity of 40-70%. Artificial lighting simulated day and night changes, and f...

Embodiment 2

[0056] Example 2 Protective effect of DANK on ischemic injury of PC12 cells

[0057] 2.1 Test material

[0058] Cell line: PC12 rat adrenal pheochromocytoma clone, provided by the Cell Bank of Shanghai Chinese Academy of Sciences.

[0059] 2.2 Experimental model: PC12 cells were induced hypoxic injury by using sodium dithionite and low glucose medium.

[0060] 2.3 Index detection: MTT method, the OD value of each group was measured with an enzyme-linked immunosorbent assay at a wavelength of 570nm, and the cell viability was compared.

[0061] 2.4 Groups and results:

[0062] 2.4.1 Cell morphology observation

[0063] PC12 cell is a commonly used nerve cell line, the shape of the cell is fusiform and triangular, and the synapses are interwoven into a network with strong refractive index. After hypoxia treatment, the protrusions of the cells decreased or disappeared, the cells swelled and became round, the refractive index decreased, and some cells were lysed into fragments...

Embodiment 3

[0070] The preparation of embodiment 3 nattokinase injection

[0071] Get purified nattokinase solution (5mg / ml) 100ml, add 4% sucrose, 4% glucose and 5% mannitol. After dissolving, filter and sterilize, pack according to 2ml per bottle, aseptically freeze-dry and seal. Use physiological saline as solvent.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a new application of nattokinase, specifically an application for preparing cerebral protective agent type drugs. The invention also provides a cerebral protective agent type medical composition. Nattokinase is used as cerebral protective agent which has clear efficacy.

Description

technical field [0001] The invention relates to a new pharmaceutical application of nattokinase, in particular to the application of nattokinase in the preparation of brain-protective agent drugs, which can be used for ischemic stroke and cerebral edema The treatment of diseases such as diseases and nervous system damage caused by various reasons belongs to the field of pharmacy. Background technique [0002] Cerebrovascular disease is the third leading cause of death in my country, of which ischemic stroke accounts for 56.6% to 80.0%, and its disability rate occupies the first place. Therefore, controlling the degree of brain damage in the early stage of disease has great economic and social benefits . In recent years, domestic and foreign patients with acute ischemic stroke have focused on early thrombolysis and neuroprotective treatment. A large number of studies on the mechanism of cerebral ischemic injury have shown that the key to neuroprotective treatment is to block...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/48A61P25/00A61P7/10A61P9/10
Inventor 陈军魏琪蒋飞代鹏何俊蓉周驿彭文璟
Owner CHENGDU DIAO JIUHONG PHARMA FAB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com